KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Paul K. Audhya Sells 3,125 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul K. Audhya sold 3,125 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.82, for a total value of $30,687.50. Following the completion of the sale, the insider now directly owns 100,334 shares of the company’s stock, valued at approximately $985,279.88. This trade represents a 3.02 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

KalVista Pharmaceuticals Stock Performance

KalVista Pharmaceuticals stock traded up $0.93 during midday trading on Wednesday, reaching $10.71. The stock had a trading volume of 515,932 shares, compared to its average volume of 304,464. The stock has a market capitalization of $529.29 million, a P/E ratio of -2.94 and a beta of 0.85. The firm’s fifty day simple moving average is $8.80 and its 200-day simple moving average is $10.43. KalVista Pharmaceuticals, Inc. has a 1-year low of $7.30 and a 1-year high of $15.50.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.01. On average, sell-side analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Institutional Trading of KalVista Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in KALV. Aquatic Capital Management LLC acquired a new stake in KalVista Pharmaceuticals in the 4th quarter valued at about $44,000. Tower Research Capital LLC TRC increased its holdings in shares of KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 5,502 shares during the last quarter. Legal & General Group Plc lifted its holdings in KalVista Pharmaceuticals by 22.5% during the 4th quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 1,494 shares during the last quarter. Martin Worley Group acquired a new stake in KalVista Pharmaceuticals during the 4th quarter valued at $86,000. Finally, China Universal Asset Management Co. Ltd. boosted its position in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock worth $87,000 after purchasing an additional 2,043 shares during the period.

Analyst Ratings Changes

Several equities research analysts have commented on the stock. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. JMP Securities initiated coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. Needham & Company LLC restated a “buy” rating and set a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Finally, TD Cowen initiated coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $30.00 price target for the company. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).